Fosamax Medicaid Coverage by State Tier

Why Medicaid Coverage Tier Matters for Alendronate

Medicaid formulary tiers directly control your out-of-pocket cost and whether your pharmacist can dispense without extra steps. Alendronate is one of the most widely covered generic drugs in the United States, but placement varies enough across state programs that knowing your state's specific tier can save a patient meaningful money and prevent unnecessary delays.

How State Medicaid Formularies Are Structured

Each state manages its own Medicaid preferred drug list (PDL). The Centers for Medicare and Medicaid Services (CMS) sets outer limits on cost-sharing under 42 CFR 447.52, but states choose tier structure independently. CMS nominal cost-sharing rules cap most generic copays at $4 for beneficiaries above the federal poverty level.

Tier 1 (preferred generic) carries the lowest copay, usually $0, $4. Tier 2 (non-preferred generic or preferred brand) runs $4, $8. Tier 3 or higher (non-preferred brand) may require prior authorization (PA) and cost $8 or more. Generic alendronate almost universally sits at Tier 1. Brand Fosamax, if listed at all, typically sits at Tier 3 with a PA requirement.

FDA-Approved Indications That Affect Coverage Decisions

The FDA approved alendronate for postmenopausal osteoporosis (prevention and treatment), osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone. FDA label for alendronate sodium tablets specifies standard doses of 10 mg daily or 70 mg once weekly for treatment. Coverage decisions track these labeled indications closely. A PA request for an off-label use, such as prevention in a patient with a T-score above the treatment threshold, faces higher denial rates.

The U.S. Preventive Services Task Force (USPSTF) recommends screening for osteoporosis in women aged 65 and older and in younger postmenopausal women at increased risk. USPSTF osteoporosis screening recommendation (2018) provides the clinical backbone that many state Medicaid programs use to define covered indications. States that have adopted the USPSTF recommendation verbatim typically cover alendronate without PA for women 65 and older with a confirmed low bone density diagnosis.

Alendronate Medicaid Coverage State by State

State Medicaid programs update their PDLs quarterly. The table below reflects publicly posted PDLs as of early 2026. Always verify with your state Medicaid agency or pharmacy benefit manager (PBM) before dispensing.

States Where Generic Alendronate Is Tier 1, No PA Required

The majority of states, including California (Medi-Cal), Texas (STAR/CHIP), New York (Medicaid), Florida, Pennsylvania, Ohio, Michigan, Illinois, Georgia, and North Carolina, place generic alendronate 70 mg on Tier 1 with no prior authorization for patients with a diagnosis of osteoporosis (ICD-10 M81.0 or M80.00). Copays range from $0 to $3.

Medi-Cal, the largest state Medicaid program covering more than 14 million Californians, lists alendronate 70 mg weekly as a preferred generic with a $0 copay for most beneficiaries. The Medi-Cal pharmacy benefits information is maintained by the California Department of Health Care Services.

States With Tier 1 Coverage But Diagnosis Verification Required

Several states, including Arizona (AHCCCS), Colorado, Washington (Apple Health), Oregon (OHP), and Minnesota (MA), cover alendronate at Tier 1 but require the prescriber to document a DXA-confirmed diagnosis (T-score at or below -2.5, or a fragility fracture) in the prior-authorization form. This is less restrictive than a full PA; a brief clinical attestation from the prescribing provider typically suffices.

The National Osteoporosis Foundation (Bone Health and Osteoporosis Foundation) defines treatment thresholds in its clinical guidelines. BHOF 2022 clinical practice guideline recommends pharmacologic therapy for postmenopausal women with a T-score at or below -2.5 or a 10-year FRAX hip fracture probability at or above 3%. Most state Medicaid programs cite equivalent thresholds when requiring diagnosis verification.

States With Brand Fosamax on a Higher Tier

Brand-name Fosamax (Merck) sits at Tier 3 or is not listed as a separately payable brand in most state PDLs because generic alendronate passed the FDA's bioequivalence threshold. FDA bioequivalence guidance for alendronate confirms that approved generics meet the same quality standards as the reference listed drug. States including Texas, Florida, and New York will typically deny a brand claim when the generic is available, citing therapeutic equivalence.

A prescriber seeking brand Fosamax for a specific clinical reason, such as a documented intolerance to the inactive ingredients in available generics, must submit a PA with documented evidence of that intolerance. Approvals in this scenario are possible but take 5 to 15 business days in most states.

Clinical Evidence Supporting Alendronate Use

State Medicaid PA reviewers often reference published fracture-reduction data when evaluating requests for alendronate outside standard indications. Knowing the key trial data strengthens PA appeals.

Fracture Intervention Trial (FIT)

The Fracture Intervention Trial enrolled 6,459 postmenopausal women with low bone mass. At 3 years, alendronate reduced the risk of hip fracture by 47% (relative risk 0.53, 95% CI 0.31 to 0.90, P<0.05) and vertebral fracture by 55% compared with placebo. FIT trial, Black DM et al., Lancet 1996 remains the foundational efficacy citation for bisphosphonate coverage decisions.

FLEX Extension

The Fracture Intervention Trial Long-Term Extension (FLEX) followed 1,099 women for up to 10 years. Women who discontinued alendronate after 5 years maintained bone density better than those who never treated, and clinical fracture rates were similar to those who continued for 10 years, except for a higher risk of clinical vertebral fracture in the discontinuation group. FLEX trial, Black DM et al., JAMA 2006 informs current guidelines on drug holidays, which state PA reviewers may cite when evaluating re-authorization requests.

Glucocorticoid-Induced Osteoporosis Coverage

Medicaid coverage for alendronate in glucocorticoid-induced osteoporosis (GIOP) follows the American College of Rheumatology (ACR) 2022 GIOP guideline. ACR 2022 guideline on GIOP, Buckley L et al., Arthritis Care Res 2023 conditionally recommends alendronate as a first-line oral option for patients on prednisone 2.5 mg per day or more for 3 months or longer when fracture risk is moderate to high. States that have adopted ACR criteria cover alendronate for GIOP without additional PA beyond the diagnosis and steroid dose documentation.

Bone Mineral Density and DXA Scan Requirements

Several states require a baseline DXA scan result before approving alendronate claims, even for generic Tier 1 coverage. The International Society for Clinical Densitometry (ISCD) and the USPSTF both endorse DXA as the reference standard. USPSTF DXA evidence review notes that DXA at the lumbar spine and femoral neck is the accepted method. If a patient has not had a DXA scan, most state Medicaid programs cover the scan itself under preventive benefits for eligible patients.

How to Get Alendronate Cheaper: Discount Programs and Savings Strategies

Even patients without Medicaid or with high commercial insurance copays have several options to reduce the cost of alendronate significantly.

GoodRx and Pharmacy Discount Programs

Generic alendronate 70 mg (4 tablets, 28-day supply) is available at major pharmacies for as low as $4 using GoodRx at Costco and Walmart as of early 2026. The GoodRx drug pricing database updates in real time. These discount cards work in lieu of insurance but cannot be combined with Medicaid in most states due to federal anti-kickback rules under 42 U.S.C. 1320a-7b.

Patient Assistance Programs

Merck does not maintain an active patient assistance program (PAP) for brand Fosamax given the wide availability of cheap generics. However, NeedyMeds (needymeds.org) and RxAssist catalog state pharmaceutical assistance programs and manufacturer bridge programs that may cover alendronate for uninsured patients who are not Medicaid-eligible. The NeedyMeds alendronate listing aggregates current programs.

$4 Generic Programs at Major Chains

Walmart, Kroger, Publix, and Costco maintain $4 or $5 generic drug lists that include alendronate 70 mg weekly. These programs do not require any coupon or enrollment and represent the most direct access pathway for uninsured patients. At these prices, a full year of treatment costs $48, $60 out of pocket. The FDA generic drug savings report notes that generic drugs save the U.S. Healthcare system more than $300 billion annually, underscoring why alendronate's low cash price is both sustainable and widely available.

Biosimilar and Therapeutic Alternatives Covered by Medicaid

If alendronate causes GI side effects, Medicaid may cover alternative bisphosphonates. Risedronate (Actonel) is on Tier 1 in most state PDLs as well. Zoledronic acid (Reclast) 5 mg IV once yearly is covered under the medical benefit in most states for patients who cannot tolerate oral bisphosphonates. A 2022 Cochrane review of bisphosphonates for osteoporosis confirmed that all oral bisphosphonates reduce vertebral fracture risk, providing the clinical justification for therapeutic substitution when needed.

Prior Authorization: How to Win the Appeal

When a state Medicaid program denies alendronate or requires PA, the appeal process follows a defined structure. Knowing what reviewers look for reduces denial rates.

What PA Reviewers Require

Most state PA forms for alendronate request: confirmed osteoporosis or osteopenia diagnosis with ICD-10 code, DXA T-score result (lumbar spine or femoral neck), FRAX 10-year fracture probability if T-score is between -1.0 and -2.5, prescriber NPI and DEA numbers, and duration of requested therapy (typically 12 months, renewable).

The WHO FRAX tool is the standard fracture risk calculator and is referenced in BHOF, ACR, and USPSTF guidance. A FRAX hip fracture probability at or above 3% or a major osteoporotic fracture probability at or above 20% meets the pharmacologic treatment threshold in all major U.S. Guidelines. NOF/BHOF clinical guideline, Cosman F et al., Osteoporos Int 2014 establishes these thresholds formally.

Step Therapy Requirements

A minority of states (including some managed care organizations within Medicaid) impose step therapy, requiring a 3- to 6-month trial of calcium and vitamin D supplementation before approving alendronate. The ACR position statement on step therapy does not support step therapy as a prerequisite for pharmacologic treatment when the fracture risk threshold is met. Prescribers can cite BHOF or ACR guidelines to appeal step-therapy mandates successfully.

Expedited PA for High-Risk Patients

Patients with a recent fragility fracture (hip, vertebral, wrist) qualify for expedited PA in most states under CMS guidance. The CMS Medicaid managed care final rule (2016) requires managed care plans to process urgent PA requests within 72 hours. Documenting the fracture in the PA request and noting fracture liaison service (FLS) involvement, where available, accelerates approval.

Alendronate Dosing and Administration: What Medicaid Prescriptions Must Specify

Medicaid claims systems match the prescribed quantity against the approved indication. Prescribing the wrong formulation or frequency can trigger an automatic claim denial.

Approved Doses and Their NDC Codes

The 70 mg once-weekly tablet is the most common formulation prescribed and the one on most Tier 1 PDLs. The 10 mg daily tablet is therapeutically equivalent but less frequently dispensed. The 70 mg tablet with cholecalciferol 2,800 IU (Fosamax Plus D) occupies a separate NDC and may sit on a different tier. FDA drug database for alendronate NDC listings lists every approved alendronate product.

Oral solution (70 mg per 75 mL weekly) is available for patients with swallowing difficulties and is covered under most state PDLs, though quantities must match the oral solution format (one bottle per week). Prescribers should verify the exact NDC with the dispensing pharmacy before submitting PA paperwork to avoid a format mismatch.

Administration Instructions That Affect Tolerability

Alendronate must be taken on an empty stomach with 6 to 8 oz of plain water, and the patient must remain upright for at least 30 minutes after ingestion. FDA prescribing information for alendronate warns that failure to follow these instructions increases the risk of esophageal irritation, the most common reason patients discontinue therapy and request a Medicaid formulary exception for an alternative agent.

Monitoring Requirements That Affect Annual PA Renewal

Most state Medicaid PA renewals for alendronate require documentation of tolerability and, in some states, a repeat DXA scan every 2 years. The ISCD 2019 official positions on DXA monitoring intervals recommend repeat DXA at 1 to 2 years after initiating therapy to confirm a treatment response, then every 2 years once stability is established. Including the most recent DXA result in the annual PA renewal strengthens the clinical record and speeds approval.

Alendronate vs. Alternatives: Medicaid Coverage Comparison

Understanding how alendronate compares with other osteoporosis drugs on state formularies helps prescribers choose the most accessible option when alendronate is inappropriate.

| Drug | Typical Medicaid Tier | PA Required | Approximate Annual Cost (Generic) | |---|---|---|---| | Alendronate 70 mg weekly | Tier 1 | No (most states) | $48, $100 | | Risedronate 35 mg weekly | Tier 1 to 2 | No/Sometimes | $100, $200 | | Ibandronate 150 mg monthly | Tier 2 to 3 | Yes (many states) | $300, $600 | | Zoledronic acid 5 mg IV yearly | Medical benefit | Yes | $500, $1,200 | | Denosumab (Prolia) 60 mg SQ q6m | Tier 3/specialty | Yes | $2,400, $4,800 | | Raloxifene 60 mg daily | Tier 1 to 2 | No/Sometimes | $200, $400 |

Alendronate's position as the lowest-cost, broadest-coverage option makes it the first-line choice in virtually all state Medicaid formularies. A 2019 analysis published in the Journal of Bone and Mineral Research confirmed that adherence to oral bisphosphonates at 12 months predicts fracture outcomes more strongly than drug selection among available agents, reinforcing the case for selecting the most accessible (lowest-barrier) agent first.

HSA and FSA Eligibility for Alendronate

Alendronate is a qualifying medical expense under IRS Publication 502. Patients with a health savings account (HSA) or a flexible spending account (FSA) can use pre-tax funds to pay for alendronate at any licensed pharmacy. IRS Publication 502, Medical and Dental Expenses lists prescription drugs as eligible expenses. There is no minimum out-of-pocket amount required; even a $4 GoodRx purchase qualifies.

HSA and FSA funds cannot be combined with Medicaid copays for the same claim, but uninsured patients or patients on commercial insurance with a high deductible can use HSA/FSA funds to cover the full cash price. For a patient paying $4 per 28-day supply out of pocket, a full year of alendronate costs $48, which a $50 FSA contribution covers entirely.